EasySep™人CD34正选试剂盒 II

人CD34+细胞的免疫磁珠正选

产品号 #(选择产品)

产品号 #17856_C

人CD34+细胞的免疫磁珠正选

产品优势

  • 快捷、操作简单    
  • 纯度高达99%
  • 无需分离柱     

产品组分包括

  • EasySep™人CD34正选试剂盒 II(产品号 #17856)
    • EasySep™人CD34正选抗体混合物,1 x 1 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,1 x 1 mL
    • EasySep™人CD34正选试剂盒 II(产品号 #100-1569)
    • EasySep™人CD34正选抗体混合物,1 x 10 mL
    • EasySep™ Dextran RapidSpheres™ 50103磁珠,1 x 1 mL
  • RoboSep™人CD34正选试剂盒 II(含过滤吸头,产品号 #17856RF)
    • EasySep™人CD34正选抗体混合物,1 x 1 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,1 x 1 mL
    • RoboSep™ 缓冲液(产品号 #20104)
    • RoboSep™过滤吸头(产品号 #20125)
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

总览

使用EasySep™人CD34正选试剂盒 II,通过免疫磁珠正选可从新鲜或冻存的动员人外周血、骨髓单个核细胞 (MNCs)、冻存的脐带血MNCs、人胚胎干 (ES) 或诱导多能干 (iPS) 细胞中分离高纯度的CD34+细胞。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性,迄今已广泛应用于发表的研究中超过20年。    

在此EasySep™正选过程中,目的细胞被识别CD34的抗体复合物和 磁珠结合标记,抗体复合物中还含有人Fc受体阻断剂 ,可最大程度减少非特异性结合。使用EasySep™磁极分离标记的目的细胞,通过简单倾倒即可去除非目标细胞,而目标细胞则保留在管中。磁珠分选后获得的人CD34+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD34抗原表达于造血干细胞和祖细胞表面。

该产品可替代EasySep™人CD34正选试剂盒 (产品号 #18056) 以进行更快的细胞分选。

如需从动员白细胞单采术样本中大规模分离人CD34+细胞,请选用大容量(1 x 10^10细胞)试剂盒(产品号 #100-1569)。

了解更多关于免疫磁珠EasySep™技术的工作原理,或如何通过RoboSep™实现全自动化免疫磁珠细胞分选 。探索更多优化您实验流程的产品 ,包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)
 
亚型
细胞分选试剂盒
 
细胞类型
造血干/祖细胞,多能干细胞
 
种属

 
样本来源
Bone Marrow,Cord Blood,其它细胞系,PBMC,多能干细胞,Whole Blood,Mobilized Leukopaks
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep,RoboSep
 
研究领域
嵌合体,免疫,干细胞生物学
 

Data Figures

Typical EasySep™ Human CD34 Positive Selection Kit II Isolation Profile

Figure 1. Typical EasySep™ Human CD34 Positive Selection Kit II Isolation Profile

Starting with cord blood, mobilized peripheral blood or bone marrow MNCs, or ES and iPS cell cultures, the CD34+ cell content of the isolated fraction is typically 93.5 ± 1.1% (mean ± SD), using the purple EasySep™ Magnet. In the above example using frozen cord blood, the purities of the start and final isolated fractions are 2.2% and 94.7%, respectively.

FACS Data for Anti-Human CD34 Antibody, Clone 581, Alexa Fluor® 488-Conjugated

Figure 2. FACS Data for Anti-Human CD34 Antibody, Clone 581, Alexa Fluor® 488-Conjugated

(A) Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD34 Antibody, Clone 581, Alexa Fluor® 488 (Catalog #60013AD) and Anti-Human CD45 Antibody, Clone HI30, APC (Catalog #60018AZ). (B) Flow cytometry analysis of PBMCs labeled with Mouse IgG1, kappa Isotype Control Antibody, Clone MOPC-21, Alexa Fluor® 488 (Catalog #60070AD), and Anti-Human CD45 Antibody, Clone HI30, APC. (C) Flow cytometry analysis of human PBMCs processed with the EasySep™ Human CD34 Positive Selection Kit (Catalog #17856) and labeled with Anti-Human CD34 Antibody, Clone 581, APC. Histograms show labeling of PBMCs (Start) and isolated cells (Isolated). Labeling of start cells with Mouse IgG1, kappa Isotype Control Antibody, Clone MOPC-21, Alexa Fluor® 488 is shown (solid line histogram).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-1569
Lot #
All
Language
English
Catalog #
17856, 17856RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17856, 17856RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17856, 17856RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17856RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (13)

Publications (12)

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial. R. Yen et al. Leukemia 2022 oct

Abstract

Despite the effectiveness of tyrosine kinase inhibitors (TKIs) against chronic myeloid leukemia (CML), they are not usually curative as some patients develop drug-resistance or are at risk of disease relapse when treatment is discontinued. Studies have demonstrated that primitive CML cells display unique miRNA profiles in response to TKI treatment. However, the utility of miRNAs in predicting treatment response is not yet conclusive. Here, we analyzed differentially expressed miRNAs in CD34+ CML cells pre- and post-nilotinib (NL) therapy from 58 patients enrolled in the Canadian sub-analysis of the ENESTxtnd phase IIIb clinical trial which correlated with sensitivity of CD34+ cells to NL treatment in in vitro colony-forming cell (CFC) assays. We performed Cox Proportional Hazard (CoxPH) analysis and applied machine learning algorithms to generate multivariate miRNA panels which can predict NL response at treatment-na{\{i}}ve or post-treatment time points. We demonstrated that a combination of miR-145 and miR-708 are effective predictors of NL response in treatment-na{\"{i}}ve patients whereas miR-150 and miR-185 were significant classifiers at 1-month and 3-month post-NL therapy. Interestingly incorporation of NL-CFC output in these panels enhanced predictive performance. Thus this novel predictive model may be developed into a prognostic tool for use in the clinic."
Enhancement of proliferation of human umbilical cord blood-derived CD34+ hematopoietic stem cells by a combination of hyper-interleukin-6 and small molecules. Y. S. Park et al. Biochemistry and biophysics reports 2022 mar

Abstract

Umbilical cord blood (UCB) is an alternative source of allogeneic hematopoietic stem cells (HSCs) for transplantation to treat various hematological disorders. The major limitation to the use of UCB-derived HSCs (UCB-HSCs) in transplantation, however, is the low numbers of HSCs in a unit of cord blood. To overcome this limitation, various cytokines or small molecules have been used to expand UCB-HSCs ex vivo. In this study, we investigated a synergistic effect of the combination of HIL-6, SR1, and UM171 on UCB-HSC culture and found that this combination resulted in the highest number of CD34+ cells. These results suggest that the combination of SR1, UM171 and HIL-6 exerts a synergistic effect in the proliferation of HSCs from UCB and thus, SR1, UM171 and HIL-6 is the most suitable combination for obtaining HSCs from UCB for clinical transplantation.
Asymmetric organelle inheritance predicts human blood stem cell fate. D. Loeffler et al. Blood 2022 mar

Abstract

Understanding human hematopoietic stem cell fate control is important for its improved therapeutic manipulation. Asymmetric cell division, the asymmetric inheritance of factors during division instructing future daughter cell fates, was recently described in mouse blood stem cells. In human blood stem cells, the possible existence of asymmetric cell division remained unclear because of technical challenges in its direct observation. Here, we use long-term quantitative single-cell imaging to show that lysosomes and active mitochondria are asymmetrically inherited in human blood stem cells and that their inheritance is a coordinated, nonrandom process. Furthermore, multiple additional organelles, including autophagosomes, mitophagosomes, autolysosomes, and recycling endosomes, show preferential asymmetric cosegregation with lysosomes. Importantly, asymmetric lysosomal inheritance predicts future asymmetric daughter cell-cycle length, differentiation, and stem cell marker expression, whereas asymmetric inheritance of active mitochondria correlates with daughter metabolic activity. Hence, human hematopoietic stem cell fates are regulated by asymmetric cell division, with both mechanistic evolutionary conservation and differences to the mouse system.

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000) • Easy 250 EasySep™ Magnet (Catalog #100-0821)
Sample Source Bone Marrow, Cord Blood, Mobilized Leukopaks, Other, PBMC, Pluripotent Stem Cells, Whole Blood
Selection Method Positive
标记抗体
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。